Navigation Links
Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/6/2008

ase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual result
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
5. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
6. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
7. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
8. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
9. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
10. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... CHESTERBROOK, Pa. , Sept. 29, 2014 /PRNewswire/ ... of the largest global pharmaceutical sourcing and distribution ... analysis on coffee consumption. This research was analyzed ... coffee consumption was associated with an increase in ... The study looked at population-level coffee consumption across ...
(Date:9/27/2014)... the peer-reviewed Journal of Animal Science concludes ... has no impact on the health or productivity of ... and field data sets, the article documents evidence that ... crops are comparable with those of animals fed non-GE ... feed crops have become an increasing component of livestock ...
(Date:9/27/2014)... Researchers from The University of Texas at Dallas have ... wearable computers with self-contained power sources or, more immediately, ... of heavy use. , This technology, published online in ... power of a single electron to control energy consumption ... modern electronic systems. , Researchers from the Erik Jonsson ...
(Date:9/26/2014)... , Sept. 26, 2014  MicroBiome Therapeutics ... results from a proof of concept study testing ... the tolerability of metformin, the first-line therapy for ... of metformin and active ingredients contained in the ... an effective, safe and inexpensive medication, is recommended ...
Breaking Biology Technology:Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3New UT Dallas technology may lead to prolonged power in mobile devices 2New UT Dallas technology may lead to prolonged power in mobile devices 3Positive Proof Of Concept Study Shows MicroBiome Therapeutics' NM505 May Improve Tolerability Of Metformin In Type 2 Diabetes 2Positive Proof Of Concept Study Shows MicroBiome Therapeutics' NM505 May Improve Tolerability Of Metformin In Type 2 Diabetes 3
... Calif., May 6 Finesse Solutions, LLC,Santa ... control solutions for,life sciences process applications, announced ... of Software. Basil brings over 19 years ... a focus on,implementing high efficiency engineering, resource ...
... Award at Leading Venture Contest Makes Carnegie Mellon ,Winningest, ... ... time, a team of,students from the Tepper School of Business at Carnegie ... competition Moot,Corp(R). This year,s winning venture business -- NeuroBank -- has developed,a ...
... Md., May 6 PharmAthene, Inc.,(Amex: PIP ) ... threats, announced today that its financial results,for the first ... 13, 2008., PharmAthene management will be hosting a ... The call is scheduled to begin at,4:30 p.m. Eastern ...
Cached Biology Technology:Basil Zimmo Joins Finesse Solutions as Vice-President of Software 2Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition 2PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008 2
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 populations ... the globe dropped 52 percent, says the 2014 ... Fund (WWF). This biodiversity loss occurs disproportionately in ... of high-income countries. , In addition to the ... point to other warning signs about the overall ...
(Date:9/29/2014)... Texas at Arlington research team says recently identified radiation ... lab could open doors for homeland security and medical ... the Oct. 1 issue of Optics Letters , ... describe a new method to fabricate transparent nanoscintillators by ... a transparent ceramic is formed. A scintillator refers ...
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3New VCU center to target cocaine addiction 2
... of a tiny shrimp-like species, known scientifically as ... non-native quagga mussels in the Great Lakes, say NOAA ... Diporeia and many aquatic species have steadily ... NOAA,s Great Lakes Environmental Laboratory published,this week in ...
... University have developed a new tool that makes it possible ... generation of blood vessels. The researchers, findings, published in ... enable scientists to determine what signals in the body attract ... tumor research. The new invention is a tiny cell ...
... a startling result, a new study published by the ... than 80 percent of the world,s major armed conflicts ... biologically diverse and threatened places on Earth. Titled ... conservation scientists compared major conflict zones with the Earth,s ...
Cached Biology News:Tiny tool to control growing blood vessels opens new potential in tumor research 2Study finds most wars occur in Earth's richest biological regions 2Study finds most wars occur in Earth's richest biological regions 3
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
... in hybridization incubators with rotators. Graduated, ... size PP plug-seal screw-cap with O-ring ... three lengths to accept different size ... O-rings available separately. • Comp Dim: ...
Biology Products: